This feature highlights changes in clinical trial organizations’ personnel.

Actimed Therapeutics

Frank Misselwitz has been named chief medical officer of Actimed Therapeutics. Most recently, Misselwitz was corporate vice president and therapeutic area head in clinical development at Bayer.

Almirall

Almirall has named Gianfranco Nazzi as its new CEO. Nazzi was most recently executive vice president of the international markets region at Teva Pharmaceuticals.

Aquestive Therapeutics

Aquestive Therapeutics has appointed Mark Lepore as chief medical officer for allergy. Lepore was formerly the vice president and head of clinical strategy and development at Lupin Pharmaceuticals.

bit.bio

Ramy Ibrahim has been named chief medical officer at bit.bio. Formerly, Ibrahim was chief medical officer at the Parker Institute for Cancer Immunotherapy.

Butterfly Network

Todd Fruchterman has been named president and CEO of Butterfly Network. Fruchterman was formerly president and general manager of medical solutions at 3M.

CytoSorbents

David Cox has been named vice president of global regulatory affairs at CytoSorbents. Most recently, Cox was vice president of regulatory affairs at Integra LifeSciences.

Eurofins Discovery

Eurofins Discovery has named Paul Ratcliffe the leader of the company’s integrated drug discovery business unit DiscoveryOne. Ratcliffe was formerly head of innovation hubs at Grünenthal Group.

Exacis Biotherapeutics

Exacis Biotherapeutics has appointed Dirk Huebner to the role of chief medical officer. Huebner was recently the chief medical officer at Mersana Therapeutics.

Indapta Therapeutics

Indapta Therapeutics has appointed Lori Kunkel to senior clinical adviser. Kunkel was formerly acting chief medical officer at Loxo Oncology. The company has also named Robert Sikorski, former chief medical officer at FivePrime Therapeutics, as founding chief medical officer.

Jnana Therapeutics

Jnana Therapeutics has named Nick Pullen as senior vice president and head of biology. Pullen previously held the role of vice president at Bristol Myers Squibb.

Kymera Therapeutics

Kymera Therapeutics has named Ashwin Gollerkeri senior vice president and head of development. Formerly, Gollerkeri was vice president of clinical sciences at Array BioPharma.

MedPharm

Jon Lenn has been named chief scientific officer at MedPharm. Most recently, Lenn was the company’s chief technology officer.

Novavax

Madelyn Caltabiano has been named senior vice president of global program management at Novavax. Formerly, Caltabiano was senior vice president of global project and alliance management at Merck Research Laboratories.

Novo Nordisk

Marcus Schindler, senior vice president and head of global drug discovery at Novo Nordisk, has been promoted to chief scientific officer of the company. Before Novo Nordisk, Schindler was vice president and head of cardiovascular and metabolic disease at AstraZeneca.

Oasmia Pharmaceutical

Heidi Ramstad has been named chief medical officer of Oasmia Pharmaceutical. Ramstad was formerly the chief medical officer for Nisonic.

OncoDNA

OncoDNA has named Bernard Courtieu the company’s new CEO. Courtieu was most recently the CEO of IntegraGen.

OncXerna Therapeutics

Colleen Mockbee has been named chief development officer and senior vice president of regulatory affairs at OncXerna Therapeutics.

Pharmaceutical Research and Manufacturers of America (PhRMA)

Ramona Sequeira, president of Takeda Pharmaceuticals USA, has been named board chair-elect of PhRMA. Sequeira will still serve as president of the U.S. business unit at Takeda Pharmaceutical. Before her role at Takeda, she was the vice president of sales and operations at Eli Lilly.

QurAlis

Has appointed Kevin Leach to senior vice president of translational science and portfolio strategy. Leach was formerly the vice president of nonclinical and translational research at Spring Bank Pharmaceuticals.

Roivant Sciences

Matthew Gline, former chief financial officer of Roivant Sciences, has been promoted to CEO of the company.

Stilla Technologies

Philippe Mourere has taken the helm of Stilla Technologies as its new CEO. Mourere was recently the senior vice president of commercial and business development at HalioDx.